Europe Cell and Gene Therapy Market – Focused Insights 2024-2029

EUROPE CELL AND GENE THERAPY MARKET INSIGHTS

The cell and gene therapy market in Europe was valued at USD 2.26 billion in 2023 and is projected to reach USD 14.45 billion by 2029, expanding at a compound annual growth rate (CAGR) of 36.26% over the forecast period. Market growth is being driven by the growing interest from biopharmaceutical companies, the rising number of regenerative medicine firms, increased funding, supportive government initiatives, priority designations, and RMAT (Regenerative Medicine Advanced Therapy) policies.

Furthermore, the market is benefiting from the growing use of innovative products in clinical trials, rising demand for comprehensive treatment solutions for serious illnesses, and increased healthcare spending on cell and gene therapies across European nations.

MARKET DEFINITION

Cell & gene therapies (CGT) are advanced medicinal products that treat severe diseases such as rare diseases, cancer, and other communicable and non-communicable diseases. Increasing research and development in the cell and gene therapy segment recently boosted market growth. Further, this report offers market size & forecast data for the cell & gene therapy market in Europe. The revenue generated from the sale of cell & gene therapies is included in the report. This market covers commercial cell & gene therapy products, gene therapy-based products such as CAR-T, and oncolytic virus therapies. Cell therapies sourced from mesenchymal stem cells, cell-based immune modulation therapies, and cell/tissue-based products derived from patients' blood are also included. Still, tissue grafts/scaffolds with synthetic mechanical structures are excluded. This report provides a comprehensive and current market scenario of the Europe cell & gene therapy market, including Europe cell & gene therapy market size, anticipated market forecast, relevant market segmentations, and industry trends.

MARKET DRIVERS

European Funding Initiatives for Cell and Gene Therapies (CGTs)

In recent years, the growth of investments in cell and gene therapy (CGT) projects has been largely driven by U.S.-based companies. In 2021, CGT investment in the U.S. rose by 53% compared to the previous year, while Europe saw an 8% decline in funding. To align with global trends, Europe must secure additional funding to offset the investment shortfall from 2021. Increased collaboration and investment from the European pharmaceutical sector into academic CGT research are essential. Government initiatives can play a key role in fostering such partnerships and encouraging further investment, strengthening Europe’s position in the biopharma landscape. These efforts can also attract more private capital and skilled professionals, helping to revitalize the European CGT market.

Growing Utilization of Cell and Gene Therapy (CGT) Products in Disease Treatment

Cell and gene therapy solutions are used to treat and diagnose a wide range of diseases by replacing, inactivating, or introducing genes into the body. These therapies offer a unique approach to disease management, distinct from traditional treatments. Significant advancements have been made in oncology, where cell and gene therapies have enabled targeted and personalized treatment options—contributing significantly to market growth. Over the past few decades, evolving technologies and the rise of personalized medicine have fueled demand for these therapies. In terms of disease diagnosis and treatment, cell therapies are primarily applied in areas such as cancer, diabetes, genetic disorders, musculoskeletal conditions, eye diseases, and more. According to the Medicines in Development report, over 250 products are currently in development targeting a broad spectrum of diseases.

EUROPE CELL AND GENE THERAPY MARKET INSIGHTS

1. By Product: In 2023, the gene therapy segment held the largest share of the European cell and gene therapy market. The growing focus on gene therapy research and advancements is expected to drive further market expansion. The increasing use of gene therapies for disease diagnosis, growing investments in small and medium-sized manufacturing companies, and the rapid surge in new drug applications are set to create new opportunities and fuel market growth in the coming years.
2. By Application: The oncology application segment is experiencing notable growth, with the fastest-growing compound annual growth rate (CAGR) of over 38% during the forecast period. The strong success rates of cell and gene therapy solutions in treating cancer, their widespread application across various cancer types, and the substantial investment and rapid advancements in oncology regenerative medicines are key factors driving the growth of this segment.
3. By End-User: The hospital end-user segment holds the largest share of the European cell and gene therapy market. This growth is driven by increasing collaborations and partnerships between manufacturers and hospitals, the transition from traditional hospital settings to gene therapy production, rising demand for advanced therapy medicines over conventional treatments, and new revenue opportunities for healthcare systems, including in-house cell and gene therapy manufacturing. These factors are significantly contributing to the expansion of the hospital segment in the cell and gene therapy market.

REGIONAL ANALYSIS

In 2023, Germany held the largest share of over 21% in the European cell and gene therapy market. The country is leading in cell and gene therapy advancements, driven by substantial investments from both the public and private sectors, which are accelerating the development of its cell and gene therapy market. Germany is actively engaged in the development and testing of innovative medicines within this field, providing significant benefits to patients.

COMPETITIVE LANDSCAPE

The Europe cell and gene therapy market report features exclusive data on 36 vendors. The market is highly competitive, driven by an increasing number of biopharmaceutical companies developing innovative therapies. Additionally, growing financial support and government initiatives for regenerative medicines and advanced medicinal products are benefiting key players in the market. Leading players in the European CGT market include Novartis, Gilead Sciences, Amgen, F. Hoffmann-La Roche, Orchard Therapeutics, BioMarin Pharmaceutical, PTC Therapeutics, Bristol-Myers Squibb, Organogenesis, Smith & Nephew, Legend Biotech, CSL Ltd, Vertex Pharmaceuticals Inc., and Human Stem Cells Institute PJSC. These companies are competing with emerging players and expanding their market share through inorganic growth strategies.